Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.
2.

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Deng K, Adams MM, Damani P, Livingston PO, Ragupathi G, Gin DY.

Angew Chem Int Ed Engl. 2008;47(34):6395-8. doi: 10.1002/anie.200801885. No abstract available.

PMID:
18624313
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cancer vaccines targeting carbohydrate antigens.

Livingston PO, Ragupathi G.

Hum Vaccin. 2006 May-Jun;2(3):137-43. Epub 2006 May 16.

PMID:
17012906
[PubMed - indexed for MEDLINE]
Free Article
4.

Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

Kim YJ, Wang P, Navarro-Villalobos M, Rohde BD, Derryberry J, Gin DY.

J Am Chem Soc. 2006 Sep 13;128(36):11906-15.

PMID:
16953631
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Synthesis of the potent immunostimulatory adjuvant QS-21A.

Wang P, Kim YJ, Navarro-Villalobos M, Rohde BD, Gin DY.

J Am Chem Soc. 2005 Mar 16;127(10):3256-7.

PMID:
15755124
[PubMed - indexed for MEDLINE]
6.

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

Carcaboso AM, Hernández RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL.

Vaccine. 2004 Mar 29;22(11-12):1423-32.

PMID:
15063565
[PubMed - indexed for MEDLINE]
7.

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, Daubenberger CA, Guzman F, Pluschke G, Patarroyo ME.

Vaccine. 2002 May 22;20(17-18):2263-77.

PMID:
12009282
[PubMed - indexed for MEDLINE]
8.

Studies on the synthesis of landomycin A: synthesis and glycosidation reactions of L-rhodinosyl acetate derivatives.

Roush WR, Bennett CE, Roberts SE.

J Org Chem. 2001 Sep 21;66(19):6389-93.

PMID:
11559191
[PubMed - indexed for MEDLINE]
9.

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D; NIAID AIDS Vaccine Evaluation Group.

Vaccine. 2001 Feb 28;19(15-16):2080-91.

PMID:
11228380
[PubMed - indexed for MEDLINE]
10.

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO.

Vaccine. 2000 Oct 15;19(4-5):530-7.

PMID:
11027818
[PubMed - indexed for MEDLINE]
11.

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity.

Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, Farmer JT, Koratich MS, May RD.

Vaccine. 2000 Jul 15;18(27):3141-51.

PMID:
10856794
[PubMed - indexed for MEDLINE]
12.

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO.

Int J Cancer. 2000 Mar 1;85(5):659-66.

PMID:
10699946
[PubMed - indexed for MEDLINE]
13.

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO.

Vaccine. 1999 Nov 12;18(7-8):597-603.

PMID:
10547417
[PubMed - indexed for MEDLINE]
14.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.

Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO.

Clin Cancer Res. 1998 Nov;4(11):2669-76.

PMID:
9829729
[PubMed - indexed for MEDLINE]
Free Article
15.

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, Okuda K.

J Virol. 1998 Jun;72(6):4931-9.

PMID:
9573261
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.

Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO.

Int J Cancer. 1997 Sep 26;73(1):50-6.

PMID:
9334809
[PubMed - indexed for MEDLINE]
17.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO.

Int J Cancer. 1997 Sep 26;73(1):42-9.

PMID:
9334808
[PubMed - indexed for MEDLINE]
18.

Isomerization and formulation stability of the vaccine adjuvant QS-21.

Cleland JL, Kensil CR, Lim A, Jacobsen NE, Basa L, Spellman M, Wheeler DA, Wu JY, Powell MF.

J Pharm Sci. 1996 Jan;85(1):22-8.

PMID:
8926578
[PubMed - indexed for MEDLINE]
19.

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy.

Jacobsen NE, Fairbrother WJ, Kensil CR, Lim A, Wheeler DA, Powell MF.

Carbohydr Res. 1996 Jan 4;280(1):1-14.

PMID:
8581890
[PubMed - indexed for MEDLINE]
20.

Adjuvant activity of QS-21 isomers.

Soltysik S, Bedore DA, Kensil CR.

Ann N Y Acad Sci. 1993 Aug 12;690:392-5.

PMID:
8368766
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk